MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wurch, T.
Right arrow Articles by Pauwels, P. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wurch, T.
Right arrow Articles by Pauwels, P. J.

Vol. 54, Issue 6, 1088-1096, December 1998

Chimeric Receptor Analysis of the Ketanserin Binding Site in the Human 5-Hydroxytryptamine1D Receptor: Importance of the Second Extracellular Loop and Fifth Transmembrane Domain in Antagonist Binding

Thierry Wurch, Francis C. Colpaert, and Petrus J. Pauwels

Department of Cellular and Molecular Biology, Centre de Recherche Pierre Fabre, 81106 Castres Cédex, France

The 5-hydroxytryptamine (5-HT)1B/1D receptor subtypes are involved in the regulation of 5-HT release and have gained particular interest because of their apparent role in migraine. Although selective antagonists for both receptor subtypes recently have been developed, the receptor domains involved in the pharmacological specificity of these antagonists are defined poorly. This was investigated with a chimeric 5-HT1B/1D receptor analysis and using ketanserin as a selective antagonist of h5-HT1D (h5-HT1D) Ki = 24-27 nM) as opposed to h5-HT1B (Ki = 2193-2902 nM) receptors. A domain of the h5-HT1D receptor encompassing the second extracellular loop and the fifth transmembrane domain is necessary and sufficient to promote higher affinity binding (Ki = 65-115 nM) for ketanserin to the h5-HT1B receptor. The same domain of the h5-HT1B receptor, when exchanged in the h5-HT1D receptor, abolished high affinity binding of ketanserin (Ki = 364-1265 nM). A similar observation was made with the antagonist ritanserin and seems specific because besides the unmodified binding affinities for 5-HT and zolmitriptan, only minor modifications (2-4-fold) were observed for the agonists L 694247 and sumatriptan and the antagonists GR 127935 and SB 224289. Generating point mutations of divergent amino acids compared with the h5-HT1B receptor did not demonstrate a smaller peptide region related to a significant modification of ketanserin binding. The antagonists ketanserin and ritanserin are likely to bind the h5-HT1D receptor by its second extracellular loop, near the exofacial surface of the fifth transmembrane domain, or both.


Copyright © 1998 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
D. Yin, S. Gavi, H.-y. Wang, and C. C. Malbon
Probing Receptor Structure/Function with Chimeric G-Protein-Coupled Receptors
Mol. Pharmacol., June 1, 2004; 65(6): 1323 - 1332.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
L. Shi and J. A. Javitch
The second extracellular loop of the dopamine D2 receptor lines the binding-site crevice
PNAS, January 13, 2004; 101(2): 440 - 445.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
M. T. Piascik and D. M. Perez
alpha 1-Adrenergic Receptors: New Insights and Directions
J. Pharmacol. Exp. Ther., August 1, 2001; 298(2): 403 - 410.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
R. Brys, K. Josson, M. P. Castelli, M. Jurzak, P. Lijnen, W. Gommeren, and J. E. Leysen
Reconstitution of the Human 5-HT1D Receptor-G-Protein Coupling: Evidence for Constitutive Activity and Multiple Receptor Conformations
Mol. Pharmacol., June 1, 2000; 57(6): 1132 - 1141.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
D. J. J. Waugh, R. J. Gaivin, M. J. Zuscik, P. Gonzalez-Cabrera, S. A. Ross, J. Yun, and D. M. Perez
Phe-308 and Phe-312 in Transmembrane Domain 7 Are Major Sites of alpha 1-Adrenergic Receptor Antagonist Binding. IMIDAZOLINE AGONISTS BIND LIKE ANTAGONISTS
J. Biol. Chem., June 29, 2001; 276(27): 25366 - 25371.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1998 by the American Society for Pharmacology and Experimental Therapeutics